当前位置: X-MOL 学术Nat. Rev. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Breast cancer: Short-term NAT reveals resistance
Nature Reviews Clinical Oncology ( IF 78.8 ) Pub Date : 2017-09-05 00:00:00 , DOI: 10.1038/nrclinonc.2017.143
David Killock

Many breast-cancer-related deaths are attributable to recurrence of resected oestrogen receptor positive (ER+) tumours after adjuvant endocrine therapy. A study in 143 women with stage I–III ER+/HER2− breast cancer indicates that short-term neoadjuvant therapy (NAT) followed by genetic tumour profiling can not only uncover, but

中文翻译:

乳腺癌:短期NAT显示耐药性

许多乳腺癌相关的死亡可归因于辅助内分泌治疗后切除的雌激素受体阳性(ER +)肿瘤的复发。一项针对143例I–III期ER + / HER2–乳腺癌女性的研究表明,短期新辅助疗法(NAT)继之以基因肿瘤图谱分析不仅可以发现,而且可以
更新日期:2017-09-20
down
wechat
bug